LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2

AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…

LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases

Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.

LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science

Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.

10 new data-driven health companies selected for KQ Labs accelerator programme

10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…

LifeArc invests in company developing personalised drug and digital combination treatments

LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.

Three new Trustees bring more skills and experience to LifeArc

A very warm welcome to three new Trustees who have joined our Board.

LifeArc invests in Cumulus Neuroscience

Investment part of £6 million funding round led by Dementia Discovery Fund, supported by UK Future Fund

LifeArc co-leads £6 million funding in DJS Antibodies

LifeArc announces Seed Fund investment of £2 million in DJS Antibodies, a biotech start-up company pioneering the…

LifeArc and Future Fund provide £3.0m in funding to Avvinity Therapeutics

Funding to help drive the development of new cancer therapies